Exonuclease 1 is a Potential Diagnostic and Prognostic Biomarker in Hepatocellular Carcinoma.

Front Mol Biosci

The Key Laboratory of Molecular Biology of Infectious Diseases Designated By the Chinese Ministry of Education, Chongqing Medical University, Chongqing, China.

Published: June 2022

AI Article Synopsis

  • Hepatocellular carcinoma (HCC) is a major global health issue, with a pressing need for effective biomarkers to facilitate early diagnosis and improve patient survival rates.
  • This study focused on Exonuclease 1 (EXO1) to explore its potential as a diagnostic and prognostic biomarker in HCC by evaluating its expression levels across various cancer databases and analyzing its links with immune cell activity and genetic alterations.
  • Findings indicated that EXO1 expression is notably elevated in HCC tissues and serum, correlating with poor prognosis, tumor characteristics, and involvement in key cell proliferation pathways, thereby highlighting its significance in HCC diagnostics and treatment strategies.*

Article Abstract

Hepatocellular carcinoma (HCC) represents a global health challenge. Effective biomarkers are required for an early diagnosis to improve the survival rates of HCC patients. Exonuclease 1 (EXO1) plays a significant role in the DNA repair and recombination mechanisms. This study aimed to investigate the diagnostic and prognostic roles of EXO1 in HCC. We analyzed the EXO1 expression levels in various cancers including HCC from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. RNA sequencing data were analyzed using the R packages to determine differentially expressed genes (DEGs) between high- and low-EXO1 expressing HCC tissues from the TCGA-LIHC database. A Spearman's correlation analysis was performed to determine the association between EXO1 expression and immune cell infiltration, and immune checkpoint genes and TP53. MethSurv and CBioPortal databases were used to evaluate the DNA methylation changes and genetic alterations in the gene. A logistic regression analysis was performed to determine the association between EXO1 expression and the clinicopathological characteristics of the HCC patients. The diagnostic and prognostic predictive values of EXO1 were evaluated using the Kaplan-Meier (K-M) survival curves, diagnostic receiver operating characteristic (ROC) curves, nomogram model, and Cox regression analysis. EXO1 expression levels were significantly higher in the tumor tissues and serums of HCC patients compared to the corresponding controls. The DEGs associated with EXO1 were significantly enriched in the cell proliferation pathways. EXO1 expression levels significantly correlated with immune cell infiltration, immune checkpoint genes, and TP53 in the HCC tissues. The DNA methylation status in five CpG islands of the gene was associated with the prognosis of HCC. EXO1 expression levels in the HCC tissues were associated with the tumor grades, alpha-fetoprotein (AFP) levels, and the tumor stages. Cox regression analysis showed that EXO1 was a potential independent risk factor for the overall survival (OS) and disease-specific survival (DSS) of HCC patients. ROC curve analysis showed that EXO1 expression levels accurately distinguished HCC tissues from the adjacent normal liver tissues. Our study demonstrated that EXO1 was a potential diagnostic and prognostic biomarker, and a promising therapeutic target in HCC.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234278PMC
http://dx.doi.org/10.3389/fmolb.2022.889414DOI Listing

Publication Analysis

Top Keywords

exo1 expression
28
expression levels
20
diagnostic prognostic
16
hcc patients
16
hcc tissues
16
hcc
13
exo1
13
regression analysis
12
analysis exo1
12
potential diagnostic
8

Similar Publications

The bioinformatics analysis and experimental validation of the carcinogenic role of EXO1 in lung adenocarcinoma.

Front Oncol

December 2024

Department of Pathology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

Background: Exonuclease 1 (EXO1), a protein involved in mismatch repair and recombination processes, has been identified as a prognostic biomarker in lung adenocarcinoma (LUAD). Nevertheless, its role in LUAD progression remains elusive. This study seeks to elucidate the functional significance of EXO1 in LUAD and evaluate its potential as a therapeutic target.

View Article and Find Full Text PDF

Exonuclease 1 (EXO1) is an evolutionarily conserved exonuclease, which have function on maintaining genomic stability. Elevated expression of EXO1 has been reported in certain cancers. However, a comprehensive pan-cancer analysis of EXO1 is still lacking and its role in human cancer development remains poorly understood.

View Article and Find Full Text PDF

Breast cancer stem cells (BCSCs) are a rare cell population that is responsible for tumour initiation, metastasis and chemoresistance. Despite this, the mechanism by which BCSCs withstand genotoxic stress is largely unknown. Here, we uncover a pivotal role for the arginine methyltransferase PRMT5 in mediating BCSC chemoresistance by modulating DNA repair efficiency.

View Article and Find Full Text PDF
Article Synopsis
  • Breast cancer is caused by abnormal breast cells that can form tumors, which can spread and become deadly if not treated.
  • The study aimed to understand the molecular changes from Ductal Carcinoma In Situ (DCIS) to Invasive Ductal Carcinoma (IDC) by identifying important hub genes related to this transition and potential treatments.
  • Ten key hub genes linked to tumor progression were identified, with CDK1 and DTL being significant, and the study found that the anti-inflammatory compound Fisetin effectively binds to these genes, suggesting it could help in targeting treatment for breast cancer.
View Article and Find Full Text PDF

MELATONIN ENHANCES TEMOZOLOMIDE-INDUCED APOPTOSIS IN GLIOBLASTOMA AND NEUROBLASTOMA CELLS.

Exp Oncol

October 2024

Department of Medical Biology, Faculty of Medicine, Trakya University, Edirne, Turkey.

Article Synopsis
  • The study investigates the effects of melatonin (MEL) combined with temozolomide (TMZ) on glioblastoma and neuroblastoma cancer cell lines, aiming to understand how this combination affects cell viability and resistance.
  • Results reveal that the MEL and TMZ combination significantly decreases cancer cell viability and increases apoptosis compared to other treatments, highlighting a potential strategy to counteract drug resistance in these cancers.
  • The findings suggest that this combination therapy upregulates genes involved in antioxidant defense and DNA repair, indicating a possible mechanism through which MEL enhances the efficacy of TMZ.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!